The current state of the mental health system is a conversation that echoes in the halls of policy-making, the corners of social advocacy, and within the private struggles of individuals…
Read More
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and…
Read More
Enveric Biosciences recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued…
Read More
Microcap Enveric Biosciences (NASDAQ:ENVB) is threatening to take legal action against AbbVie (NYSE:ABBV) as it believes that the latter's major depressive disorder candidate bretisilocin, which it said it would acquire…
Read More
In the rush to stake a claim in next-generation mental health treatments, biotech headlines are dominated by billion-dollar acquisitions and bold clinical projections. But in the fine print—in courtrooms, patent…
Read More
Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed…
Read More
When AbbVie wrote a $1.2 billion cheque for Gilgamesh Pharmaceuticals’ Bretisilocin, it wasn’t just buying a drug, it was buying a future. That future, once dismissed as fringe science, is now being…
Read More
There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA. After forgoing a Phase 1 in Australia and…
Read More
Enveric Biosciences (NASDAQ: ENVB) is pioneering non-hallucinogenic therapies called neurostabilogens. With FDA guidance fast-tracking its lead candidate EB-003, Enveric is positioning itself as a scalable, practical alternative to first-wave psychedelic…
Read More
When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been…
Read More
